Information Provided By: 
Fly News Breaks for March 24, 2015
GILD
Mar 24, 2015 | 08:00 EDT
After a warning was added to Gilead's HCV drugs following adverse effects in patients taking the drugs in combination with amiodarine, Bernstein believes that the label change is "a non-event." The firm does not believe that more than 0.5% of HCV patients are taking amiodarine. It keeps a $125 price target and Outperform rating on Gilead.
News For GILD From the Last 2 Days
GILD
Apr 22, 2024 | 07:19 EDT
Cantor Fitzgerald lowered the firm's price target on Gilead to $75 from $78 and keeps a Neutral rating on the shares. The firm, which made slight adjustments to all of its large-cap biotechnology models ahead of Q1 earnings season for the group, lowered its target for Gilead given slower expected HIV growth. The "usual seasonal headwinds that typically make this one of the weaker quarters for the industry," the analyst added in the preview note.
